Jiangsu Ruishi Biotechnology Co., Ltd. is a high-tech enterprise wholly owned by Shenzhen Ruishi Biotechnology Co., Ltd., integrating the research and development, production, and sales of pharmaceutical intermediates, chemical raw materials, and specialty formulations.

Leveraging the unique advantages of its β-lactamase inhibitor intermediate and active pharmaceutical ingredient (API) production base in reaction types such as azide, metal catalysis, chlorination, cryogenics, ultra-high temperature, and amination, the company develops high-difficulty specialty APIs and intermediates in areas including antivirals, cardiovascular drugs, and weight loss, providing high-value-added and cost-effective products for domestic and international pharmaceutical companies.

Simultaneously, the company possesses internationally leading core technologies such as continuous flow microreaction, asymmetric synthesis, and enzymatic catalysis, deeply participating in and supporting the development of high-end generic drugs and innovative drugs with strong clinical value and core technologies, thereby accelerating drug commercialization.

The company adheres to a strategy that balances endogenous growth and external expansion. Internally, it emphasizes R&D and innovation; externally, it deepens its industrial layout through strategic mergers and acquisitions.